Nocion Therapeutics, a biopharmaceutical company developing novel small molecule charged sodium channel blockers (nocions), for the treatment of cough, itch, and pain, announced it started a Phase 1 study of its novel inhaled cough therapy, NOC-100.
NOC-100, is an inhaled formulation of NTX-1175 (Nocion’s lead small molecule charged sodium channel blocker being developed for cough). NTX-1175 selectively affects actively firing inflamed nociceptors by entering those nociceptors through large-pore channels and inhibiting sodium channels. Previously, NTX-1175 has shown excellent efficacy in preclinical models of cough.
NOC-100 has the potential to treat both chronic and acute cough, and thus it could be useful for suppressing cough in patients with COVID-19.
As Nocion evolved to the clinical development stage, they strengthened their leadership team by hiring Christopher Silber, M.D. as Chief Medical Officer and appointing Michael Higgins to the Board of Directors.
Read more about Nocion Therapeutics here.
Photo by Anshu A on Unsplash
